CytoDyn (OTCMKTS:CYDY) Issues Quarterly Earnings Results

CytoDyn (OTCMKTS:CYDY) issued its earnings results on Monday. The biotechnology company reported ($0.01) earnings per share for the quarter, reports.

CytoDyn Price Performance

Shares of OTCMKTS:CYDY opened at $0.15 on Thursday. CytoDyn has a twelve month low of $0.13 and a twelve month high of $0.42. The stock’s 50 day moving average is $0.17 and its 200-day moving average is $0.18.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.